1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192.TWO
SynCore Biotechnology Co.,LtdTW flagTaipei Exchange
21.30
TWD
+0.80
- -
749.01MMarket Cap

Total Valuation

SynCore Biotechnology Co.,Ltd carries a market capitalization of 749.01M, placing it among publicly traded companies globally. Its enterprise value stands at 713.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap749.01M
Enterprise Value713.67M

Share Statistics

SynCore Biotechnology Co.,Ltd currently has 35.17M shares outstanding.

Shares Outstanding35.17M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 32.39, and the price-to-book ratio stands at 3.25.

PE RatioN/A
PS Ratio32.39
PB Ratio3.25
P/TBV Ratio4.20
P/FCF Ratio-23.10
P/OCF Ratio-22.85

Enterprise Valuation

EV / Sales26.39
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

SynCore Biotechnology Co.,Ltd maintains a current ratio of 21.37, meaning it holds 21.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.85, indicating moderate leverage, while an interest coverage ratio of -272.81 demonstrates limited ability to service its debt obligations.

Current Ratio21.37
Quick Ratio16.32
Debt / Equity0.85
Debt / EBITDA-0.04
Interest Coverage-272.81

Financial Efficiency

Return on Equity (ROE)-16.15
Return on Assets (ROA)-15.96
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.60

Stock Price Statistics

SynCore Biotechnology Co.,Ltd's stock has declined approximately -25.91304% over the past 52 weeks. The 50-day moving average sits at 20.37, while the 200-day moving average is 23.16.

Beta (5Y)N/A
52-Week Price Change-25.91304%
50-Day Moving Average20.37
200-Day Moving Average23.16
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, SynCore Biotechnology Co.,Ltd generated 27.04M in revenue and converted that into -45.75M in net income, yielding earnings per share of -1.30. EBITDA reached -47.20M, while operating income came in at -47.20M.

Revenue27.04M
Gross Profit21.09M
Operating Income-47.20M
Pretax Income-45.75M
Net Income-45.75M
EBITDA-47.20M
EBIT-47.20M
Earnings Per Share (EPS)-1.30

Balance Sheet

SynCore Biotechnology Co.,Ltd holds 164.41M in cash and equivalents against 2.10M in total debt, resulting in a net debt position of -157.19M. Total book value stands at 269.33M, with working capital of 205.19M providing operational flexibility.

Cash & Cash Equivalents164.41M
Total Debt2.10M
Net Debt-157.19M
Equity (Book Value)269.33M
Book Value Per Share7.66
Working Capital205.19M

Cash Flow

SynCore Biotechnology Co.,Ltd produced -38.33M in operating cash flow over the past twelve months. After subtracting -406,000.00 in capital expenditures, free cash flow totaled -38.74M - equivalent to -1.10 per share.

Operating Cash Flow-38.33M
Capital Expenditures-406,000.00
Free Cash Flow-38.74M
FCF Per Share-1.10

Margins

SynCore Biotechnology Co.,Ltd operates with a gross margin of 77.98, reflecting its pricing power and cost economics. The operating margin of -174.52 and net profit margin of -169.19 provide insight into operational efficiency.

Gross Margin77.98
Operating Margin-174.52
Pretax Margin-169.19
Profit Margin-169.19
EBITDA Margin-174.52

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.10
FCF Yield-4.33

Stock Splits

SynCore Biotechnology Co.,Ltd's most recent stock split took place on October 5, 2023 with a 200:203 split ratio.

Last Split Date10/5/2023
Split Ratio200:203

Scores

SynCore Biotechnology Co.,Ltd posts an Altman Z-Score of 52.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score52.18